TP53 and acute myeloid leukemia: Using this animal model, we have revealed that azacitidine-induced myelosuppression and other host variables, iron overload and tp53 mutations play an important role in determining the efficacy of azacitidine therapy, a standard of care regimen for the treatment of patients with MDS and AML.